[1] |
WEI Yu , ZHANG Tingwei , HE Yi , LI Jun , BI Jianbin , ZENG Yu , WAN Lijun , WU Gaoliang , WANG Huansheng , ZHANG Jun , ZHU Wei , QU Yuanyuan , ZHU Yao , YE Dingwei .
Preliminary study on efficacy and safety of fluzoparib in patients with metastatic castration-resistant prostate cancer
[J]. China Oncology, 2021, 31(7): 561-566.
|
[2] |
XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia.
The advances in immunotherapy biomarkers of small cell lung cancer
[J]. China Oncology, 2021, 31(7): 635-639.
|
[3] |
YI Weili , ZHAO Wencheng , HUANG Dongning , QIN Li , WU Xintian , ZHOU Fei , WU Fengying .
Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(3): 203-211.
|
[4] |
LU Dasong, FENG Yongjun, WANG Wufeng, MOU Zhonglin, ZHAO Na .
Influence of individualized nutrition intervention on quality of life and survival prognosis of patients with locally advanced nasopharyngeal carcinoma
[J]. China Oncology, 2021, 31(12): 1202-1208.
|
[5] |
The Society of Gynecological Cancer of China Anti-Cancer Association, Chinese Society of Pathology of the Chinese Medical Association, National Pathology Quality Control Center.
The Chinese Expert Consensus Recommendations on Molecular Testing in Endometrial Cancer (2021 edition)
[J]. China Oncology, 2021, 31(11): 1126-1144.
|
[6] |
WU Jingwen, YU Xuejuan, YANG Qiu’an.
Association between Onodera’s prognostic nutrition index and adverse effects of concurrent chemoradiotherapy for esophageal squamous cell carcinoma
[J]. China Oncology, 2020, 30(7): 525-530.
|
[7] |
WANG Jie .
Challenges and directions of immune checkpoint inhibitors in the treatment of lung cancer
[J]. China Oncology, 2020, 30(10): 744-749.
|
[8] |
ZHU Chuanying, JIANG Mawei, ZHOU Renhua, LU Dongqing, ZHOU Qing.
Clinical study of nimotuzumab combined with chemoradiotherapy in the patients with pediatric brain stem gliomas
[J]. China Oncology, 2019, 29(9): 730-735.
|
[9] |
GAO Zhiqiang,WANG Weimin,CAI Yuqing,QIN Ruoyan,GU Aiqin,XIONG Liwen,HAN Baohui,JIANG Liyan,SHI Chunlei .
Clinical efficacy of osimertinib in the treatment of 62 patients with advanced lung adenocarcinoma
[J]. China Oncology, 2019, 29(10): 809-814.
|
[10] |
YANG Youqi, OU Xiaomin, ZHOU Xin, et al.
Clinical efficacy of GP, PF and TPF chemotherapy combined with intensity-modulated radiotherapy for nasopharyngeal carcinoma
[J]. China Oncology, 2018, 28(8): 602-608.
|
[11] |
ZHANG Yingqiang, ZHANG Xin, WANG Chen, et al.
The value of 18F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy
[J]. China Oncology, 2018, 28(7): 505-510.
|
[12] |
HUANG Tao, ZHENG Hongtu, YANG Lifeng, et al.
Stenosis and distortion of reconstructed rectum after neoadjuvant chemoradiotherapy and anterior resection procedure for patients with local advanced mid-low rectal cancer: risk factors and clinical management
[J]. China Oncology, 2018, 28(4): 290-296.
|
[13] |
WANG Xiuyue, ZHAO Chuan, CHEN Che, et al.
A meta-analysis of long non-coding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma
[J]. China Oncology, 2018, 28(3): 229-235.
|
[14] |
WANG Xiaoshen, HU Chaosu.
Anti-EGFR monoclonal antibodies combined with other modalities in treatment of head and neck squamous cell carcinoma
[J]. China Oncology, 2018, 28(12): 881-887.
|
[15] |
DING Huiping, DOU Shengjin, WANG Qiong, et al.
Effect of oral nutritional supplements on nutritional status and quality of life in patients with nasopharyngeal carcinoma receiving chemoradiotherapy
[J]. China Oncology, 2018, 28(1): 62-68.
|